Published in Cancer Res on September 01, 2007
Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. Neuro Oncol (2010) 1.78
HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. Clin Cancer Res (2010) 1.65
Interleukin-13 is overexpressed in cutaneous T-cell lymphoma cells and regulates their proliferation. Blood (2015) 1.54
Engineered T cells: the promise and challenges of cancer immunotherapy. Nat Rev Cancer (2016) 1.51
Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics. Proc Natl Acad Sci U S A (2010) 1.29
Stem-like tumor-initiating cells isolated from IL13Rα2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T Cells. Clin Cancer Res (2012) 1.29
MiR-21 in the extracellular vesicles (EVs) of cerebrospinal fluid (CSF): a platform for glioblastoma biomarker development. PLoS One (2013) 1.25
Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. Mol Ther (2013) 1.25
Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment. Clin Dev Immunol (2011) 1.24
Experimental approaches for the treatment of malignant gliomas. Pharmacol Ther (2010) 1.23
Immunotherapy of malignant brain tumors. Immunol Rev (2008) 1.20
Allergy and inflammatory transcriptome is predominantly negatively correlated with CD133 expression in glioblastoma. Neuro Oncol (2009) 1.10
An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. Expert Rev Vaccines (2013) 1.08
Colocalization of gadolinium-diethylene triamine pentaacetic acid with high-molecular-weight molecules after intracerebral convection-enhanced delivery in humans. Neurosurgery (2011) 1.08
Immunotherapy advances for glioblastoma. Neuro Oncol (2014) 1.07
Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy. Clin Cancer Res (2013) 1.07
Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma. Clin Cancer Res (2015) 1.00
Gene therapy for brain tumors: basic developments and clinical implementation. Neurosci Lett (2012) 0.98
IL-13Rα2-Targeted Therapy Escapees: Biologic and Therapeutic Implications. Transl Oncol (2011) 0.93
The future of glioblastoma therapy: synergism of standard of care and immunotherapy. Cancers (Basel) (2014) 0.91
Gli1 maintains cell survival by up-regulating IGFBP6 and Bcl-2 through promoter regions in parallel manner in pancreatic cancer cells. J Carcinog (2009) 0.91
Toxin-based targeted therapy for malignant brain tumors. Clin Dev Immunol (2012) 0.91
Adoptive cell therapies for glioblastoma. Front Oncol (2013) 0.90
Effect of imaging and catheter characteristics on clinical outcome for patients in the PRECISE study. J Neurooncol (2010) 0.89
Characterization and immunotherapeutic implications for a novel antibody targeting interleukin (IL)-13 receptor α2. J Biol Chem (2012) 0.88
Engineering toxin-resistant therapeutic stem cells to treat brain tumors. Stem Cells (2015) 0.85
Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy. Neuro Oncol (2014) 0.84
Dickkopf-1 is frequently overexpressed in ovarian serous carcinoma and involved in tumor invasion. Clin Exp Metastasis (2011) 0.84
Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape. J Clin Invest (2016) 0.84
Glioma IL13Rα2 is associated with mesenchymal signature gene expression and poor patient prognosis. PLoS One (2013) 0.83
Differential glioma-associated tumor antigen expression profiles of human glioma cells grown in hypoxia. PLoS One (2012) 0.83
The TWEAK receptor Fn14 is a potential cell surface portal for targeted delivery of glioblastoma therapeutics. Oncogene (2015) 0.79
A novel single-chain antibody redirects adenovirus to IL13Rα2-expressing brain tumors. Sci Rep (2015) 0.78
Antibody-drug conjugates in glioblastoma therapy: the right drugs to the right cells. Nat Rev Clin Oncol (2017) 0.78
Targeted toxins for glioblastoma multiforme: pre-clinical studies and clinical implementation. Anticancer Agents Med Chem (2011) 0.77
Cellular immunotherapy for pediatric solid tumors. Cytotherapy (2014) 0.77
Recombinant adenovirus IL-24-Bax promotes apoptosis of hepatocellular carcinoma cells in vitro and in vivo. Cancer Gene Ther (2010) 0.77
Human Hematopoietic Signal peptide-containing Secreted 1 (hHSS1) modulates genes and pathways in glioma: implications for the regulation of tumorigenicity and angiogenesis. BMC Cancer (2014) 0.75
Cytokine induction of VCAM-1 but not IL13Rα2 on glioma cells: a tale of two antibodies. PLoS One (2014) 0.75
Membrane associated cancer-oocyte neoantigen SAS1B/ovastacin is a candidate immunotherapeutic target for uterine tumors. Oncotarget (2015) 0.75
Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell (2006) 15.16
Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation. Cancer Res (2005) 3.63
Identification of dynamically regulated microRNA and mRNA networks in developing oligodendrocytes. J Neurosci (2008) 2.95
Posterior subtemporal transtentorial approach to intraparenchymal lesions of the anteromedial region of the superior cerebellum. J Neurosurg (2005) 2.69
Effect of pregnancy on hemangioblastoma development and progression in von Hippel-Lindau disease. J Neurosurg (2012) 2.65
The natural history of hemangioblastomas of the central nervous system in patients with von Hippel-Lindau disease. J Neurosurg (2003) 2.34
Poor functional status as a risk factor for surgical site infection due to methicillin-resistant Staphylococcus aureus. Infect Control Hosp Epidemiol (2008) 2.33
Neurofibromatosis type 2. Lancet (2009) 2.24
Magnetic resonance imaging properties of convective delivery in diffuse intrinsic pontine gliomas. J Neurosurg Pediatr (2014) 2.07
Effect of concentration on the accuracy of convective imaging distribution of a gadolinium-based surrogate tracer. J Neurosurg (2011) 1.87
Characterization of the blood-brain barrier of metastatic and primary malignant neoplasms. J Neurosurg (2013) 1.86
Mechanisms of morbid hearing loss associated with tumors of the endolymphatic sac in von Hippel-Lindau disease. JAMA (2007) 1.73
Retracted Application and implementation of selective tissue microdissection and proteomic profiling in neurological disease. Neurosurgery (2009) 1.69
Real-time imaging of convection-enhanced delivery of viruses and virus-sized particles. J Neurosurg (2007) 1.68
A clinico-genetic study of renal coloboma syndrome in children. Pediatr Nephrol (2007) 1.59
Long-term natural history of neurofibromatosis Type 2-associated intracranial tumors. J Neurosurg (2012) 1.59
Metastases to hemangioblastomas in von Hippel-Lindau disease. J Neurosurg (2006) 1.58
Long-term natural history of hemangioblastomas in patients with von Hippel-Lindau disease: implications for treatment. J Neurosurg (2006) 1.55
Serotonin transporters in the midbrain of Parkinson's disease patients: a study with 123I-beta-CIT SPECT. J Nucl Med (2003) 1.53
von Hippel-Lindau disease-associated hemangioblastomas are derived from embryologic multipotent cells. PLoS Med (2007) 1.52
Direct interstitial infusion of NK1-targeted neurotoxin into the spinal cord: a computational model. Am J Physiol Regul Integr Comp Physiol (2003) 1.50
Interventional MRI-guided putaminal delivery of AAV2-GDNF for a planned clinical trial in Parkinson's disease. Mol Ther (2011) 1.50
Reversal of cerebral vasospasm via intravenous sodium nitrite after subarachnoid hemorrhage in primates. J Neurosurg (2011) 1.47
Convection-enhanced delivery of M13 bacteriophage to the brain. J Neurosurg (2012) 1.42
Cochlear implantation for hearing loss associated with bilateral endolymphatic sac tumors in von Hippel-Lindau disease. Otol Neurotol (2007) 1.41
Induction of IL-17 and nonclassical T-cell activation by HIV-Tat protein. Proc Natl Acad Sci U S A (2013) 1.41
Philanthropy funding for neurosurgery research and program development. Neurosurgery (2013) 1.40
Effects of anesthetic agents and fasting duration on 18F-FDG biodistribution and insulin levels in tumor-bearing mice. J Nucl Med (2005) 1.39
Immediate titanium mesh cranioplasty for treatment of postcraniotomy infections. World Neurosurg (2011) 1.39
The history of pituitary surgery for Cushing disease. J Neurosurg (2011) 1.38
Empirical antimicrobial therapy for bloodstream infection due to methicillin-resistant Staphylococcus aureus: no better than a coin toss. Infect Control Hosp Epidemiol (2009) 1.38
Developmental arrest of angioblastic lineage initiates tumorigenesis in von Hippel-Lindau disease. Cancer Res (2003) 1.38
Hemangioblastomas share protein expression with embryonal hemangioblast progenitor cell. Cancer Res (2006) 1.34
Safety and efficacy of convection-enhanced delivery of gemcitabine or carboplatin in a malignant glioma model in rats. J Neurosurg (2003) 1.30
Immunologic privilege in the central nervous system and the blood-brain barrier. J Cereb Blood Flow Metab (2012) 1.30
Image-guided convection-enhanced delivery of muscimol to the primate brain. J Neurosurg (2010) 1.29
Clinical and financial outcomes due to methicillin resistant Staphylococcus aureus surgical site infection: a multi-center matched outcomes study. PLoS One (2009) 1.28
StemCellDB: the human pluripotent stem cell database at the National Institutes of Health. Stem Cell Res (2012) 1.28
Neurologic manifestations of von Hippel-Lindau disease. JAMA (2008) 1.26
The effect of surgical site infection on older operative patients. J Am Geriatr Soc (2009) 1.24
Mechanistic and therapeutic implications of angiogenesis in endometriosis. Reprod Sci (2008) 1.24
Real-time, image-guided, convection-enhanced delivery of interleukin 13 bound to pseudomonas exotoxin. Clin Cancer Res (2006) 1.23
Experimental approaches for the treatment of malignant gliomas. Pharmacol Ther (2010) 1.23
Surgical management of brainstem hemangioblastomas in patients with von Hippel-Lindau disease. J Neurosurg (2003) 1.21
Transcriptional regulation of rod photoreceptor homeostasis revealed by in vivo NRL targetome analysis. PLoS Genet (2012) 1.19
Safety and feasibility of long-term intravenous sodium nitrite infusion in healthy volunteers. PLoS One (2011) 1.19
Hematuria and proteinuria in a mass school urine screening test. Pediatr Nephrol (2005) 1.17
Real-time in vivo imaging of the convective distribution of a low-molecular-weight tracer. J Neurosurg (2005) 1.17
N-CoR pathway targeting induces glioblastoma derived cancer stem cell differentiation. Cell Cycle (2007) 1.17
Prospective evaluation of radiosurgery for hemangioblastomas in von Hippel-Lindau disease. Neuro Oncol (2009) 1.17
Effect of ependymal and pial surfaces on convection-enhanced delivery. J Neurosurg (2008) 1.17
Image-guided convection-enhanced delivery of gemcitabine to the brainstem. J Neurosurg (2007) 1.17
Management of von Hippel-Lindau disease-associated CNS lesions. Expert Rev Neurother (2011) 1.16
The deadly toll of invasive methicillin-resistant Staphylococcus aureus infection in community hospitals. Clin Infect Dis (2008) 1.16
A prototype MR insertable brain PET using tileable GAPD arrays. Med Phys (2013) 1.15
No evidence for mouse pancreatic beta-cell epithelial-mesenchymal transition in vitro. Diabetes (2007) 1.14
Missense mutations in the NF2 gene result in the quantitative loss of merlin protein and minimally affect protein intrinsic function. Proc Natl Acad Sci U S A (2011) 1.13
Tumors of the endolymphatic sac in patients with von Hippel-Lindau disease: implications for their natural history, diagnosis, and treatment. J Neurosurg (2005) 1.13
Effect of nosocomial bloodstream infections on mortality, length of stay, and hospital costs in older adults. J Am Geriatr Soc (2014) 1.12
Effects of VHL deficiency on endolymphatic duct and sac. Cancer Res (2005) 1.11
Convective delivery of glial cell line-derived neurotrophic factor in the human putamen. J Neurosurg (2007) 1.11
A clinical and molecular genetic study of hypophosphatemic rickets in children. Pediatr Res (2005) 1.10
Decreased glucocerebrosidase activity in Gaucher disease parallels quantitative enzyme loss due to abnormal interaction with TCP1 and c-Cbl. Proc Natl Acad Sci U S A (2010) 1.09
Primary focal segmental glomerular sclerosis in children: clinical course and prognosis. Pediatr Nephrol (2006) 1.09
Renal manifestations of Dent disease and Lowe syndrome. Pediatr Nephrol (2007) 1.09
Therapeutic targeting based on gene-expression profiling in vestibular schwannomas. J Neurosurg (2014) 1.07
Histone deacetylase inhibitors prevent the degradation and restore the activity of glucocerebrosidase in Gaucher disease. Proc Natl Acad Sci U S A (2011) 1.06
18F-FDG PET in patients with esophageal squamous cell carcinoma undergoing curative surgery: prognostic implications. J Nucl Med (2004) 1.06
Surgical management of cerebellar hemangioblastomas in patients with von Hippel-Lindau disease. J Neurosurg (2008) 1.06
Augmented 18F-FDG uptake in activated monocytes occurs during the priming process and involves tyrosine kinases and protein kinase C. J Nucl Med (2004) 1.06
Prognostic significance of vascular endothelial growth factor expression and microvessel density in esophageal squamous cell carcinoma: comparison with positron emission tomography. Ann Surg Oncol (2006) 1.06
Complete factor H deficiency-associated atypical hemolytic uremic syndrome in a neonate. Pediatr Nephrol (2007) 1.05
Idiopathic membranous nephropathy in children. Pediatr Nephrol (2006) 1.05
Variable phenotype of Pierson syndrome. Pediatr Nephrol (2008) 1.04
Selective ablation of nociceptive neurons for elimination of hyperalgesia and neurogenic inflammation. J Neurosurg (2005) 1.03
The 1p-encoded protein stathmin and resistance of malignant gliomas to nitrosoureas. J Natl Cancer Inst (2007) 1.03
In-training factors predictive of choosing and sustaining a productive academic career path in neurological surgery. Neurosurgery (2012) 1.03
Mutational analysis of idiopathic renal hypouricemia in Korea. Pediatr Nephrol (2005) 1.02
Infratentorial craniospinal irradiation for von Hippel-Lindau: a retrospective study supporting a new treatment for patients with CNS hemangioblastomas. Neuro Oncol (2011) 1.02
Symptomatic epidural hematoma caused by lumbar synovial cyst rupture: report of two cases and review of the literature. Neurosurgery (2005) 1.02
Atypical hemolytic uremic syndrome associated with complement factor H autoantibodies and CFHR1/CFHR3 deficiency. Pediatr Res (2009) 1.02
Endolymphatic sac tumor demonstrated by intralabyrinthine hemorrhage. Case report. J Neurosurg (2007) 1.02
Functional outcome after resection of spinal cord hemangioblastomas associated with von Hippel-Lindau disease. J Neurosurg Spine (2010) 1.02
The effect of a PP2A inhibitor on the nuclear receptor corepressor pathway in glioma. J Neurosurg (2010) 1.01
Maternal immune activation by LPS selectively alters specific gene expression profiles of interneuron migration and oxidative stress in the fetus without triggering a fetal immune response. Brain Behav Immun (2012) 1.01
Familial focal segmental glomerulosclerosis associated with an ACTN4 mutation and paternal germline mosaicism. Am J Kidney Dis (2008) 1.00
Global protein conjugation by ubiquitin-like-modifiers during ischemic stress is regulated by microRNAs and confers robust tolerance to ischemia. PLoS One (2012) 1.00
Curcumin and dehydrozingerone derivatives: synthesis, radiolabeling, and evaluation for beta-amyloid plaque imaging. J Med Chem (2006) 1.00
Vitamin D 1alpha-hydroxylase gene mutations in patients with 1alpha-hydroxylase deficiency. J Clin Endocrinol Metab (2007) 1.00
Poor functional status is an independent predictor of surgical site infections due to methicillin-resistant Staphylococcus aureus in older adults. J Am Geriatr Soc (2010) 0.99
Surgical resection of endolymphatic sac tumors in von Hippel-Lindau disease: findings, results, and indications. Laryngoscope (2012) 0.98
Angiogenic factors stimulate growth of adult neural stem cells. PLoS One (2010) 0.98
Genetic basis of Bartter syndrome in Korea. Nephrol Dial Transplant (2011) 0.98
Convection-enhanced delivery for the treatment of pediatric neurologic disorders. J Child Neurol (2008) 0.98
Decreased renal uptake of (99m)Tc-DMSA in patients with tubular proteinuria. Pediatr Nephrol (2009) 0.98
Clinical outcomes of childhood lupus nephritis: a single center's experience. Pediatr Nephrol (2006) 0.98
Laparoscopic approach for the retrieval of retained video capsule endoscopy. JSLS (2007) 0.97
Identification of endothelin 2 as an inflammatory factor that promotes central nervous system remyelination. Brain (2013) 0.97
β-Catenin signaling initiates the activation of astrocytes and its dysregulation contributes to the pathogenesis of astrocytomas. Proc Natl Acad Sci U S A (2012) 0.96
Preferential killing of PTEN-null myelomas by PI3K inhibitors through Akt pathway. Oncogene (2003) 0.96